RPRXRoyalty Pharma

Median target
$66
calls from the last 12 months
Implied return
+12.0%
median target vs. price
Coverage
5 analysts · 6 calls
updated in the last 12 months
Consensus
5/0/0+5 net
Buy / Hold / Sell

Which analysts are behind RPRX's consensus?

See every current rating, price target and the analysts' track records for Royalty Pharma — plus the full analyst rankings, firm analytics and screener.

The consensus above reflects 5 analysts with calls on RPRX updated in the last 12 months. Implied return is the move implied if the consensus target were hit. These are forward-looking predictions, not realized returns. Per-analyst ratings and track records are a Premium feature.

RPRX elsewhere on AnalystEdge

The most recent congressional, executive-branch and insider filings matched to this ticker. Matched by ticker symbol — occasional mismatches are possible. Not investment advice.

Trending today: not in any of today's trending tables (Gaining attention, Losing attention, Most followed)

DateSourceWhoActionDetailAmount
2026-08-18InsidersHite ChristopherEVP & Chairman, PartneriInsider sale100.0K sh @ $59.97 · planned trade$6.0M
2026-08-13InsidersCoyne Terrance P.EVP & CFOInsider sale9.2K sh @ $58.59 · planned trade$541K
2026-08-13InsidersCoyne Terrance P.EVP & CFOInsider sale1.8K sh @ $59.14 · planned trade$105K
2026-04-07ExecutiveTrump, Donald JPresidentSaleRoyalty Pharma plc$1,001 - $15,000
2025-10-15ExecutiveTrump, Donald JPresidentPurchaseROYALTY PHARMA PLC CL A$1,001 - $15,000
2025-04-28ExecutiveLandau, ChristopherDeputy SecretarySaleRoyalty Pharma plc Class A Ordinary Shares (RPRX)$100,001 - $250,000
2025-04-17ExecutiveTrump, Donald JPresidentPurchaseROYALTY PHARMA PLC CL A$1,001 - $15,000
2025-04-04ExecutiveTrump, Donald JPresidentSaleRoyalty Pharma plc$1,001 - $150,004
2025-04-03ExecutiveTrump, Donald JPresidentPurchaseRoyalty Pharma plc$1,001 - $150,004
2025-01-30ExecutiveTrump, Donald JPresidentPurchaseRoyalty Pharma plc$15,001 - $500,001

More: insider activity · executive branch · trending